Translational Subcommittee: Arun Azad and Anthony Joshua
Over the past year, the Translational Research Subcommittee (TRS) has been highly productive with several Translational Research Subcommittee (TRS) meetings held.
ANZUP remains steadfast in its commitment to making translational research a cornerstone of the organisation’s mission and the TRS has been instrumental in facilitating this goal by spearheading translational research activities for ANZUP-led trials.
ANZUP Trials - Translational Research Activity
Recruitment for this trial concluded in July 2023. An interim analysis is planned after 120 events have occurred. We intend to submit a PCF Challenge grant application aimed at developing composite biomarkers to examine effect on range of endpoints for enzalutamide vs enzalutamide plus lutetium PSMA.
The final recruitment for this trial was 62/70 patients. ANZUP is looking at possible collaboration opportunities for the KEYPAD translational work.
A grant from Merck to support the TR work has been secured. The work will be undertaken at ONJCC and Merck Singapore with the first results expected by end of 2023.
The translational contract agreements for the various projects are at different stages of finalisation.
Genomic analysis has commenced on plasma samples that were sent to AWY’s Vancouver lab in September 2023. Meanwhile, DNA extraction on 180 baseline samples has been completed, and data on ctDNA fraction values will be available shortly.
The Canadian cooperative group are running a Phase II trial comparing lutetium PSMA vs docetaxel and are seeking funding for TR work. It is proposed to submit a joint PCF Challenge grant application for this Canadian trial and for TheraP. The team will be working on the proposal.
We held discussions with ImmunityBio at ASCO GU 2023 and they are keen to work with ANZUP, including TR work.
This trial is recruiting well and we have discussed potential TR work. The next steps will involve prioritizing TR ideas and sourcing funding.
The international TR committee for ENZAMET/ENZARAD will be providing governance oversight for ENZARAD TR work as for ENZAMET TR proposals. Consumer representation will be included in the governance structure.
This is a follow up study to SUBDUE. It is a proposed phase I/II trial of sub-urothelial atezolizumab in NMIBC Discussions are continuing and if it proceeds it will include TR work.
As of 31 March 54 out of 200 patients have been recruited, and sequential blood samples are being collected for future TR work (mRNA371).
Preliminary discussions are underway regarding TR work of this trial.
Caris Life Sciences proposal
The team has met with George Sledge from Caris Life Sciences (CLS) at ASCO GU. CLS would like to partner with ANZUP on molecular diagnostic research. CLS would offer access to its molecular diagnostic platform (including machine learning/artificial intelligence) in exchange for access to ANZUP clinical outcome data. There was support from committee members to explore this opportunity further.
It’s suggested that TR work for ENZARAD and DASL-HiCAP begin prior to clinical endpoint data becoming available.
IDEA GENERATION WORKSHOPS
The TR idea generation workshop was held on 8 April 2022 and had 2 concepts presented and 12 people attend.
We express our gratitude to the patients and families who participate in our trials and generously donate bio-specimens that facilitate our translational research. Without these exceptional samples, our work would not be possible. Additionally, we would like to recognise the meticulous efforts of the participating sites in obtaining correlative samples from our ANZUP trials.
Looking ahead, the Translational Research Subcommittee anticipates another fruitful year of research activities for ANZUP.